Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Stroke

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 74 articles:
HTML format



Single Articles


    November 2022
  1. NISHIZAKI Y, Miyauchi K, Iwata H, Inoue T, et al
    Study Protocol and Baseline Characteristics of Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA, The Combination of a Randomized Control Trial and an Observational Bioma
    Am Heart J. 2022 Nov 10. pii: S0002-8703(22)00282.
    PubMed     Abstract available


  2. GODOY LC, Farkouh ME, Austin PC, Shah BR, et al
    Predicting left main stenosis in stable ischemic heart disease using logistic regression and boosted trees.
    Am Heart J. 2022 Nov 10. pii: S0002-8703(22)00289.
    PubMed     Abstract available


  3. LEE M, Ahmed ZV, Huang J, Brice A, et al
    Antiplatelet regimens following carotid artery revascularization.
    Am Heart J. 2022;253:48-52.
    PubMed     Abstract available


    August 2022
  4. FRIEDMAN DJ, Pierre D, Wang Y, Gambone L, et al
    Development and Validation of an Automated Algorithm for Endpoint Adjudication for a Large U.S. National Registry: Short Title: Automated Adjudication Algorithm.
    Am Heart J. 2022 Aug 22. pii: S0002-8703(22)00168.
    PubMed     Abstract available


  5. KRANENDONK J, Willems LH, Vijver-Coppen RV, Coenen M, et al
    CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD).
    Am Heart J. 2022 Aug 18. pii: S0002-8703(22)00163.
    PubMed     Abstract available


    July 2022
  6. SUZUKI Y, Kaneko H, Yano Y, Okada A, et al
    Glycemic status and the association of change in blood pressure with incident cardiovascular disease.
    Am Heart J. 2022 Jul 21. pii: S0002-8703(22)00148.
    PubMed     Abstract available


  7. AKINYELURE OP, Colantonio LD, Chaudhary NS, Jaeger BC, et al
    Inflammation biomarkers and incident coronary heart disease: The Reasons for Geographic and Racial Differences in Stroke Study.
    Am Heart J. 2022 Jul 7. pii: S0002-8703(22)00144.
    PubMed     Abstract available


    May 2022
  8. OKAZAKI O, Higashino Y, Yokoya K, An Y, et al
    Prognosis of elderly non-valvular atrial fibrillation patients stratified by B-type natriuretic peptide: ELDERCARE-AF subanalysis.
    Am Heart J. 2022 May 11. pii: S0002-8703(22)00094.
    PubMed     Abstract available


  9. HUIJBOOM HFM, Maarse M, Aarnink E, van Dijk VF, et al
    COMPARE LAAO: Rationale and design of the randomized controlled trial 'COMPARing Effectiveness and safety of Left Atrial Appendage Occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagul
    Am Heart J. 2022 May 7. pii: S0002-8703(22)00085.
    PubMed     Abstract available


  10. CANTOR WJ, Tan M, Berwanger O, Lavi S, et al
    Morphine and Clinical Outcomes in Patients with ST segment elevation Myocardial Infarction Treated with Fibrinolytic and Antiplatelet Therapy: Insights from the TREAT Trial.
    Am Heart J. 2022 May 6. pii: S0002-8703(22)00089.
    PubMed     Abstract available


  11. WAZNI O, Boersma L, Healey JS, Mansour M, et al
    Comparison of Anticoagulation with Left Atrial Appendage Closure after AF Ablation: Rationale and Design of the OPTION randomized trial.
    Am Heart J. 2022 May 5. pii: S0002-8703(22)00088.
    PubMed     Abstract available


  12. GAO W, Zhong X, Ma Y, Huang D, et al
    A Randomized Multicenter Trial to Evaluate Early Invasive Strategy for Patients with Acute ST-segment Elevation Myocardial Infarction Presenting 24-48 Hours from Symptom Onset: protocol of the RESCUE-MI study.
    Am Heart J. 2022 May 4. pii: S0002-8703(22)00087.
    PubMed     Abstract available


    April 2022
  13. SINGER DE, Atlas SJ, Go AS, Lopes RD, et al
    ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and Design of the GUARD-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day Patch-Based Continuous ECG Monitor.
    Am Heart J. 2022 Apr 23. pii: S0002-8703(22)00080.
    PubMed     Abstract available


    March 2022
  14. DUCROCQ G, Bhatt DL, Lee JJ, Kui N, et al
    Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI: Abbreviated title: Bleeding risk stratification of ti
    Am Heart J. 2022 Mar 20. pii: S0002-8703(22)00055.
    PubMed     Abstract available


  15. TIAN X, Zuo Y, Chen S, Meng X, et al
    Distinct triglyceride-glucose trajectories are associated with different risks of incident cardiovascular disease in normal-weight adults.
    Am Heart J. 2022 Mar 3. pii: S0002-8703(22)00047.
    PubMed     Abstract available


    February 2022
  16. JONES AE, McCarty MM, Brito JP, Noseworthy PA, et al
    Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation: Rationale and Design of the RED-AF study.
    Am Heart J. 2022 Feb 23. pii: S0002-8703(22)00042.
    PubMed     Abstract available


  17. O'NEILL WW, Anderson M, Burkhoff D, Grines CL, et al
    Improved Outcomes in Patients with Severely Depressed LVEF Undergoing Percutaneous Coronary Intervention with Contemporary Practices: Impella-Supported High-Risk Percutaneous Coronary Intervention in Patients with Severely Depressed LVEF.
    Am Heart J. 2022 Feb 19. pii: S0002-8703(22)00039.
    PubMed     Abstract available


  18. LINDER M, Higgen FL, Voigtlander L, Weimann J, et al
    Stroke events after transcatheter aortic valve implantation: Temporal relationships and affected brain regions.
    Am Heart J. 2022 Feb 8. pii: S0002-8703(22)00030.
    PubMed     Abstract available


  19. CHO MS, Kang DY, Oh YS, Lee CH, et al
    Edoxaban-Based Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Stable Coronary Disease: Rationale and Design of the Randomized EPIC-CAD Trial.
    Am Heart J. 2022 Feb 8. pii: S0002-8703(22)00023.
    PubMed     Abstract available


    January 2022
  20. BAYKANER T, Pundi K, Lin B, Lu Y, et al
    The ENHANCE-AF Clinical Trial to Evaluate an Atrial Fibrillation Shared Decision-Making Pathway: Rationale and Study Design.
    Am Heart J. 2022 Jan 26. pii: S0002-8703(22)00013.
    PubMed     Abstract available


  21. ECKMAN MH, Wise R, Knochelmann C, Mardis R, et al
    Electronic Health Record-Embedded Decision Support to Reduce Stroke Risk in Patients with Atrial Fibrillation - Study Protocol.
    Am Heart J. 2022 Jan 23. pii: S0002-8703(22)00012.
    PubMed     Abstract available


  22. GENCER B, Eisen A, Berger D, Nordio F, et al
    Edoxaban vs. Warfarin in High-risk Patients with Atrial Fibrillation: A Comprehensive Analysis of High-Risk Subgroups.
    Am Heart J. 2022 Jan 3. pii: S0002-8703(21)00499.
    PubMed     Abstract available


  23. FARJAT AE, Virdone S, Thomas LE, Kakkar AK, et al
    The importance of the design of observational studies in comparative effectiveness research: Lessons from the GARFIELD-AF and ORBIT-AF registries.
    Am Heart J. 2022;243:110-121.
    PubMed     Abstract available


  24. BUTALA NM, Song Y, Shen C, Cohen DJ, et al
    Effect of intensive versus limited monitoring on clinical trial conduct and outcomes: A randomized trial.
    Am Heart J. 2022;243:77-86.
    PubMed     Abstract available


    December 2021
  25. SIDHU MS, Lyubarova R, Bangalore S, Bonaca MP, et al
    Challenges of Long-term Dual Antiplatelet Therapy Use Following Acute Coronary Syndromes: Patient Selection for Long-term DAPT After ACS.
    Am Heart J. 2021 Dec 18. pii: S0002-8703(21)00478.
    PubMed     Abstract available


  26. ULLAL AJ, Holmes DN, Lytle BL, Matsouaka RA, et al
    Achievement and Quality Measure Attainment in Patients Hospitalized with Atrial Fibrillation: Results from the Get With The Guidelines(R) - Atrial Fibrillation (GWTG-AFIB) Registry.
    Am Heart J. 2021 Dec 18. pii: S0002-8703(21)00475.
    PubMed     Abstract available


    November 2021
  27. ANTONIO GUTIERREZ J, Ruff CT, Aday AW, Gu L, et al
    Electronic Alerts to Initiate Anticoagulation Dialogue in Patients with Atrial Fibrillation.
    Am Heart J. 2021 Nov 19. pii: S0002-8703(21)00452.
    PubMed     Abstract available


    September 2021
  28. SALAH HM, Khan Minhas AM, Khan MS, Khan SU, et al
    Trends in Hospitalizations for Heart Failure, Acute Myocardial Infarction, and Stroke in the United States from 2004-2018.
    Am Heart J. 2021 Sep 25. pii: S0002-8703(21)00238.
    PubMed     Abstract available


  29. KORSHOLM K, Damgaard D, Valentin JB, Packer EJS, et al
    Left Atrial Appendage Occlusion versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Rationale and Design of the Multicenter Randomized Occlusion-AF Trial.
    Am Heart J. 2021 Sep 16. pii: S0002-8703(21)00226.
    PubMed     Abstract available


  30. NARCISSE DI, Ford CB, Weissler EH, Lippmann SJ, et al
    The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease.
    Am Heart J. 2021;239:135-146.
    PubMed     Abstract available


  31. KIM K, Yang PS, Jang E, Yu HT, et al
    Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: A nationwide cohort study.
    Am Heart J. 2021 Sep 1. pii: S0002-8703(21)00224.
    PubMed     Abstract available


    August 2021
  32. BONNESEN MP, Diederichsen SZ, Isaksen JL, Frederiksen KS, et al
    Atrial Fibrillation Burden and Cognitive Decline in Elderly Patients Undergoing Continuous Monitoring.
    Am Heart J. 2021 Aug 21. pii: S0002-8703(21)00204.
    PubMed     Abstract available


    July 2021
  33. CHRISTENSEN DM, Butt JH, Fosbol E, Kober L, et al
    Admission Rates During a Second COVID-19 Lockdown.
    Am Heart J. 2021 Jul 15. pii: S0002-8703(21)00180.
    PubMed     Abstract available


    June 2021
  34. ABE M, Ozaki Y, Takahashi H, Ishii M, et al
    Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy.
    Am Heart J. 2021 Jun 23. pii: S0002-8703(21)00165.
    PubMed     Abstract available


  35. OVERWYK K, Yin X, Tong X, Coleman King SM, et al
    Response to letters-to-the-editor for publication: "Defect-free care trends in the Paul Coverdell National Acute Stroke Program (PCNASP), 2008-2018. American Heart Journal. 2021;232:177-184. doi:10.1016/j.ahj.2020.11.010."
    Am Heart J. 2021;236:112.
    PubMed    


  36. THOMAS S
    Re: Defect-free care trends in the Paul Coverdell National Acute Stroke Program, program, 2008-2018.
    Am Heart J. 2021;236:110-111.
    PubMed    


    May 2021
  37. SIDEBOTTOM AC, Miedema MD, Benson G, Vacquier M, et al
    The Impact of a Population-based Prevention Program on Cardiovascular Events: Findings from the Heart of New Ulm Project.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00112.
    PubMed     Abstract available


  38. MADSEN JMM, Jacobsen MRR, Sabbah M, Topal DGG, et al
    Long-Term Prognostic Outcomes and Implication of Oral Anticoagulants in Patients with New-Onset Atrial Fibrillation following ST-Segment Elevation Myocardial Infarction.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00114.
    PubMed     Abstract available


  39. SHI X, He J, Lin M, Liu C, et al
    Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00111.
    PubMed     Abstract available


    March 2021
  40. KIVINIEMI T, Bustamante-Munguira J, Olsson C, Jeppsson A, et al
    A randomized prospective multicenter trial for stroke prevention by prophylactic surgical closure of the left atrial appendage in patients undergoing bioprosthetic aortic valve surgery - LAA-CLOSURE trial protocol.
    Am Heart J. 2021 Mar 30. pii: S0002-8703(21)00087.
    PubMed     Abstract available


  41. TURAKHIA M, Sundaram V, Smith SN, Ding V, et al
    Efficacy of a Centralized, Blended Electronic and Human Intervention to Improve Direct Oral Anticoagulant Adherence: Smartphones to improve rivaroxaban ADHEREnce in Atrial Fibrillation (SmartADHERE) A Randomized Clinical Trial: SmartADHERE rivaroxaban
    Am Heart J. 2021 Mar 4. pii: S0002-8703(21)00065.
    PubMed     Abstract available


    February 2021
  42. AKAO M, Yasuda S, Kaikita K, Ako J, et al
    Rivaroxaban Monotherapy versus Combination Therapy According to Patient Risk of Stroke and Bleeding in Atrial Fibrillation and Stable Coronary Disease: AFIRE trial sub-analysis.
    Am Heart J. 2021 Feb 28. pii: S0002-8703(21)00063.
    PubMed     Abstract available


  43. GE Z, Gao XF, Kan J, Kong XQ, et al
    Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicent
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00053.
    PubMed     Abstract available


  44. CAPELL WH, Barnathan ES, Piazza G, Spyropoulos AC, et al
    Rationale and Design for the Study of Rivaroxaban to Reduce Thrombotic Events, Hospitalization and Death in Outpatients with COVID-19: the PREVENT-HD Study.
    Am Heart J. 2021 Feb 9. pii: S0002-8703(21)00033.
    PubMed     Abstract available


  45. BLUMER V, Rivera M, Corbalan R, Becker RC, et al
    Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Enrolled in Latin America: Insights from ROCKET AF.
    Am Heart J. 2021 Feb 8. pii: S0002-8703(21)00036.
    PubMed     Abstract available


  46. HUSAINI M, Esmaeeli A, Thangam M, Doering M, et al
    Synthesis of systematic reviews of percutaneous device closure of patent foramen ovale (PFO) for prevention of recurrent cryptogenic stroke: Redundant publications and methodological deficiencies.
    Am Heart J. 2021;232:57-60.
    PubMed     Abstract available


    January 2021
  47. SEN S, Redd K, Trivedi T, Moss K, et al
    Periodontal Disease, Atrial Fibrillation and Stroke.
    Am Heart J. 2021 Jan 24. pii: S0002-8703(21)00013.
    PubMed     Abstract available


  48. DE GROOT JR, Ruff CT, Murphy SA, Hamershock RA, et al
    Edoxaban versus Warfarin in Patients with Atrial Fibrillation in Relation to the Risk of Stroke: A Secondary Analysis of the ENGAGE AF-TIMI 48 Study.
    Am Heart J. 2021 Jan 22. pii: S0002-8703(21)00017.
    PubMed     Abstract available


  49. THIELE H, Freund A, Gimenez MR, de Waha-Thiele S, et al
    Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial.
    Am Heart J. 2021 Jan 8. pii: S0002-8703(21)00004.
    PubMed     Abstract available


  50. BAO X, Borne Y, Xu B, Orho-Melander M, et al
    Growth differentiation factor-15 is a biomarker for all-cause mortality but less evident for cardiovascular outcomes: a prospective study: Abbreviated title: GDF-15, all-cause mortality and CVD.
    Am Heart J. 2021 Jan 6. pii: S0002-8703(21)00002.
    PubMed     Abstract available


  51. SMILOWITZ NR, Subashchandran V, Yuriditsky E, Horowitz JM, et al
    Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19.
    Am Heart J. 2021;231:93-95.
    PubMed     Abstract available


  52. VALGIMIGLI M, Cao D, Makkar RR, Bangalore S, et al
    Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
    Am Heart J. 2021;231:147-156.
    PubMed     Abstract available


    December 2020
  53. ROME BN, Gagne JJ, Avorn J, Kesselheim AS, et al
    Non-Warfarin Oral Anticoagulant Copayments and Adherence in Atrial Fibrillation:A Population-Based Cohort Study.
    Am Heart J. 2020 Dec 21. pii: S0002-8703(20)30412.
    PubMed     Abstract available


  54. CARNICELLI AP, Hong H, Giugliano RP, Connolly SJ, et al
    Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A COllaboration between Multiple instit
    Am Heart J. 2020 Dec 6. pii: S0002-8703(20)30401.
    PubMed     Abstract available


  55. KHAN H, Hanif M, Khan MA, Mirza E, et al
    Letter to the editor: Discontinuation rates of warfarin versus direct acting oral anticoagulants in clinical practice.
    Am Heart J. 2020;230:101.
    PubMed    


    November 2020
  56. OVERWYK KJ, Yin X, Tong X, King SMC, et al
    Defect-free Care trends in the Paul Coverdell National Acute Stroke Program, 2008-2018.
    Am Heart J. 2020 Nov 27. pii: S0002-8703(20)30392.
    PubMed     Abstract available


  57. KAWASHIMA H, Soliman O, Wang R, Ono M, et al
    Rationale and design of a randomized clinical trial comparing safety and efficacy of Myval transcatheter heart valve versus contemporary transcatheter heart valves in patients with severe symptomatic aortic valve stenosis: the LANDMARK trial.
    Am Heart J. 2020 Nov 5. pii: S0002-8703(20)30368.
    PubMed     Abstract available


    October 2020
  58. NORDENSKJOLD AM, Agewall S, Atar D, Baron T, et al
    Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design.
    Am Heart J. 2020;231:96-104.
    PubMed     Abstract available


  59. SALAH HM, Al'Aref SJ, Khan MS, Al-Hawwas M, et al
    Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Am Heart J. 2020;232:10-22.
    PubMed     Abstract available


  60. NATHAN AS, Yang L, Geng Z, Dayoub EJ, et al
    Oral anticoagulant use in patients with atrial fibrillation and mitral valve repair.
    Am Heart J. 2020;232:1-9.
    PubMed     Abstract available


  61. NICHOLLS SJ, Lincoff AM, Bays HE, Cho L, et al
    Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance.
    Am Heart J. 2020 Oct 23. pii: S0002-8703(20)30346.
    PubMed     Abstract available


  62. SHAVADIA JS, Wilson J, Edmonston D, Platt A, et al
    Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease.
    Am Heart J. 2020 Oct 20. pii: S0002-8703(20)30341.
    PubMed     Abstract available


  63. GIBSON CM, Kastelein JJP, Phillips AT, Aylward PE, et al
    Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myoc
    Am Heart J. 2020 Oct 13. pii: S0002-8703(20)30335.
    PubMed     Abstract available


  64. GUIMARAES HP, de Barros E Silva PGM, Liporace IL, Sampaio RO, et al
    A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
    Am Heart J. 2020 Oct 9. pii: S0002-8703(20)30277.
    PubMed     Abstract available


  65. WIGGERS H, Kober L, Gislason G, Schou M, et al
    The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 x 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with
    Am Heart J. 2020 Oct 8. pii: S0002-8703(20)30276.
    PubMed     Abstract available


    September 2020
  66. GRUBB AF, Pumill CA, Greene SJ, Wu A, et al
    Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University medical center.
    Am Heart J. 2020 Sep 24. pii: S0002-8703(20)30264.
    PubMed     Abstract available


  67. SHAIKH A, Ochani RK, Khan MS, Riaz H, et al
    Contribution of individual components to composite endpoints in contemporary cardiovascular randomized controlled trials.
    Am Heart J. 2020 Sep 14. pii: S0002-8703(20)30254.
    PubMed     Abstract available


    August 2020
  68. KAWAKAMI H, Nolan MT, Phillips K, Scuffham PA, et al
    Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk.
    Am Heart J. 2020 Aug 18. pii: S0002-8703(20)30238.
    PubMed     Abstract available


  69. KWON S, Lee SR, Choi EK, Choe WS, et al
    Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study.
    Am Heart J. 2020;229:81-91.
    PubMed     Abstract available


  70. ELHARRAM M, Sharma A, White W, Bakris G, et al
    Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
    Am Heart J. 2020;229:40-51.
    PubMed     Abstract available


  71. MIRWAIS M, Reynolds M
    Extending physicians' reach in grasping AF symptoms.
    Am Heart J. 2020;226:250-251.
    PubMed    


    July 2020
  72. AL-KHATIB SM, Pokorney SD, Al-Khalidi HR, Haynes K, et al
    Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillati
    Am Heart J. 2020;229:110-117.
    PubMed     Abstract available


  73. LI Y, Jing Q, Wang B, Wang X, et al
    Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of t
    Am Heart J. 2020;228:1-7.
    PubMed     Abstract available


    April 2020
  74. JACKSON LR 2ND, Kim S, Blanco R, Thomas L, et al
    Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Am Heart J. 2020;226:85-93.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Stroke is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: